Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology (Nasdaq: VIR) announced that CEO George Scangos, Ph.D., will present at the 40th Annual J.P.

Rhea-AI Summary

Vir Biotechnology (Nasdaq: VIR) announced that CEO George Scangos, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 p.m. ET. This event will be held virtually, and a live webcast can be accessed via the Investors section of the Vir website. The presentation will also be archived for 30 days for later viewing.

Vir Biotechnology focuses on immunology and has developed four technology platforms to treat serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Argus Session date unavailable

-8.76% session move Open Argus

Details

News Market Reaction – VIR

The recorded move for VIR in the trading session of this news was -8.76%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 p.m. ET.

The conference will be held virtually. A live webcast of the call can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Vir Biotechnology present at the J.P. Morgan Healthcare Conference?

Vir Biotechnology will present at the J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 p.m. ET.

How can I access the Vir Biotechnology conference presentation?

The presentation can be accessed via a live webcast on the Investors section of the Vir Biotechnology website.

What is the focus of Vir Biotechnology's technology platforms?

Vir Biotechnology focuses on treating serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Is the Vir Biotechnology presentation available for later viewing?

Yes, the presentation will be archived for 30 days following the event for later viewing.